Abstract:
The study was aimed to determine the platinum-resistance biomarkers in patients with ovarian cancer. 29 platinum-resistant patients with verified serous ovarian cancer of IIIA–IIIC stages were examined, who received 6 courses of adjuvant chemotherapy with platinum preparations (cisplatin 75–100 mg/m2 intravenously with hydration and forced diuresis every 3 weeks) in the postoperative period. As control, 26 patients with non-recurrence of the disease performed for 6 months post-treatment observation (platinum-susceptible tumors) were observed. The expression of ABCA1 is higher in platinum-resistant cases of ovarian cancer. The most pronounced relationship exists between the values of survivin expression, local activity of nitric oxide, the expression of glutathione dependent enzymes, the content of catecholamines in erythrocytes, and the expression of ABCA1 transporter.
